Our comprehensive Hemophilia Treatment Center (HTC), which is located within the Oncology Institute at Long Island Jewish Medical Center, is the federally designated regional hemophilia program for Long Island. The HTC provides comprehensive multidisciplinary services to over 100 children and their families with hemophilia, von Willebrand disease and related bleeding disorders. 

Through its participation in the Hemophilia Consortium Inc, the LIJ Medical Center HTC offers its patients:

  • The lowest possible prices for clotting factor concentrate
  • Choice of all licensed products, home distribution and medical waste disposal
  • Educational programs and scientific panels for patients, families, physicians and third party payers

HTC staffing includes Suchitra S. Acharya, MD, a pediatric hematologist , and Richard A. Lipton, MD, MPH, an internal medicine hematologist. Staff also includes an orthopedist, two nurse clinicians, a genetic counselor, a social worker, a physical therapist and a dental hygienist.

The HTC provides patients with a comfortable waiting area, examination rooms and a conference room.

  • Comprehensive evaluations for children are performed on Thursdays
  • Walk-in visits with acute medical problems are accommodated Monday - Friday.

Frequently Asked Questions

What is a bleeding disorder?
Hemophilia and Von Willebrand’s disease (VWD) is one of a spectrum of chronic bleeding disorders. Von Willebrand’s disease (VWD), the most common bleeding disorder, is caused by a deficiency or defect in the von Willebrand protein which plays a major role in initiating the early steps of clotting. People with this disorder bruise easily, have frequent nosebleeds, and may experience heavy and prolonged bleeding after tooth extraction, tonsillectomy or other surgeries. Women with VWD can experience prolonged menstrual bleeding leading to a compromise in their health and quality of life. The CDC estimates that VWD affects between 1% and 2% of the U.S. population.

Hemophilia which occurs predominantly in males is a rare but well-known type of bleeding disorders in which one of several protein, also referred to as Hemophilia A (factor VIII) or Hemophilia B (factor IX) normally found in blood is either deficient or defective with patients experiencing internal bleeds into joints and tissues resulting in severe pain, swelling and permanent joint and muscle damage. The Centers for Disease Control and Prevention (CDC) estimates that hemophilia affects about 18,000 persons in the United States with around 2,000 residing in the state of New York.

What is a clotting disorder?

In addition to hemophilia and VWD, there are clotting disorders (thrombophilic disorders), a term used to define a class of inherited conditions that increases the tendency for blood clots and strokes. The CDC estimates that about 5% to 8% of the population has thrombophilia, a clotting disorder often thought of as the reverse of hemophilia because of the increased propensity for clotting. Thrombophilia affects males and females equally.

What to Expect

  • Comprehensive, multidisciplinary hemophilia care
  • Diagnostic evaluation and treatment of abnormal bleeding
  • Hemostasis planning for invasive procedures, pregnancy and childbirth
  • Personalized thrombophilia screening and thrombosis risk assessment
  • Recommendations for thromboprophylaxis and anticoagulant management during surgery.
  • Family studies and genetic counseling for inherited disorders of thrombosis and hemostasis
  • Genetic counseling, physical therapy, counseling and coordination with other subspecialty services such as Cardiology, Pulmonary, Dental, Neurology, Rheumatology, Intensive Care Units and Radiology.
  • Patient/family education, home infusion programs, assessment and treatment of bleeding and clotting episodes, community education and outreach, counseling and family support
  • Clinical research program to conduct national and international studies

Back to Top